CatSper-Based Contraceptive Vaccine
- User: Female/Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Injectable
-
Intended Duration:
- Long-Acting
- Development Stage: Discovery & Early Development
- Developer(s)/researcher(s): Rensselaer Polytechnic Institute, Yale University
Details
- API: CatSper Antigen
- Target: CatSper Channel
-
Mechanism of Action:
- Anti-Microbial
- Inhibition of Sperm Capacitation
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: Developers believe an anti-sperm vaccine could provide long-term contraceptive effect in both male and female users with fewer side effects.
Product Status
Active/Recent Early Development
History
The Bystroff Lab at Rensselaer Polytechnic Institute has led CatSper-focused contraceptive vaccine development since at least 2018. In partnership with Yale, recombinant vaccine candidates have been tested in Balb/C mice, with one candidate showing contraceptive efficacy. Results from this evaluation, published in 2023, suggested potential viability of an anti-CatSper vaccine for long-term contraceptive protection.